Q-omics provides the consensus-scored MAGI3 profile across patient tissues and cancer cell-line models. MAGI3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MAGI3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MAGI3 protein abundance shows 22,903 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight OV, KIRC, and GBM as cancer lineages where MAGI3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGI3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGI3 survival associations across molecular data types. MAGI3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGI3 RNA expression–survival associations across cancer types. High MAGI3 expression shows unfavorable associations in BLCA and DLBC, but favorable associations in OV, KIRC, HNSC and READ. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for MAGI3 RNA expression.
This table summarizes MAGI3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAGI3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGI3 shows lower tumor expression in KIRC, COAD, LUAD, LUSC, KIRP and THCA. The KIRC box plot shows higher MAGI3 RNA expression in normal versus tumor tissue (log2 FC = −1.999, t-test p < 0.001).
This table shows molecular features associated with MAGI3 in patient tissues and cancer cell lines. In patient samples, MAGI3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGI3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
